Vasodilation Responses to Non-Selective α-adrenergic Blockage of Coronary Bypass Grafts in Diabetic and Non-Diabetic Patients: In Vitro Study

Similar documents
Stable Ischemic Heart Disease. Ivan Anderson, MD RIHVH Cardiology

Relaxation responses of aortic rings from salt-loaded high calcium fed rats to potassium chloride, calcium chloride and magnesium sulphate

Importance of the third arterial graft in multiple arterial grafting strategies

Assessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington

The Comparison of the Effects of Nebivolol and Metoprolol on Erectile Dysfunction in the Cases with Coronary Artery Bypass Surgery

LESSON ASSIGNMENT Given the trade and/or generic name of an adrenergic blocking agent, classify that agent as either an alpha or beta blocker.

Systemic Pharmacology Lecture 7: Neuropharmacology

Heart disease remains the leading cause of morbidity and mortality in industrialized nations. It accounts for nearly 40% of all deaths in the United

Original Article Effects of moderate pressure distention on the proximal and distal sections of the saphenous vein

Disclosures The PREVENT IV Trial was supported by Corgentech and Bristol-Myers Squibb

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases

WHY ADMINISTER CARDIOTONIC AGENTS?

MEDICAL POLICY SUBJECT: TRANSMYOCARDIAL REVASCULARIZATION

Percutaneous Mechanical Circulatory Support for Cardiogenic Shock. 24 th Annual San Diego Heart Failure Symposium Ryan R Reeves, MD FSCAI

Ischemic Heart Disease

Chronotropic and Inotropic Effects of 3 Kinds of Alpha-Adrenergic Blockers on the Isolated Dog Atria

Journal of Chemical and Pharmaceutical Research, 2014, 6(3): Research Article. Partial agonistic property of new isolated natural compounds

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Chapter 9. Body Fluid Compartments. Body Fluid Compartments. Blood Volume. Blood Volume. Viscosity. Circulatory Adaptations to Exercise Part 4

TCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI

Vasoactive Medications. Matthew J. Korobey Pharm.D., BCCCP Critical Care Clinical Specialist Mercy St. Louis

Setting The setting was a hospital. The economic study was carried out in Australia.

ino in neonates with cardiac disorders

Circulation. Blood Pressure and Antihypertensive Medications. Venous Return. Arterial flow. Regulation of Cardiac Output.

Pharmacology - Problem Drill 11: Vasoactive Agents

-adrenergic receptor subtypes blockade on the rat myocardium inotropy

Results of Ischemic Heart Disease

The Second Best Arterial Graft:

SURGICAL MYOCARDIAL REVASCULARIZATION: ARTERIAL VS VENOUS GRAFTS, SINGLE VS MULTIPLE GRAFTS?

Special circulations, Coronary, Pulmonary. Faisal I. Mohammed, MD,PhD

Managing Hypertension in the Perioperative Arena

Adrenergic agonists Sympathomimetic drugs. ANS Pharmacology Lecture 4 Dr. Hiwa K. Saaed College of Pharmacy/University of Sulaimani

Physiological Response to Hypovolemic Shock Dr Khwaja Mohammed Amir MD Assistant Professor(Physiology) Objectives At the end of the session the

Is bypass surgery needed for elderly patients with LMT disease? From the surgical point of view

Cardiac Output MCQ. Professor of Cardiovascular Physiology. Cairo University 2007

Myocardial enzyme release after standard coronary artery bypass grafting

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing

Use of Magnesium Sulphate in the Prophylaxis of Atrial Fibrillation Post Cardiac Surgery, is it Effective?

The MAIN-COMPARE Study

CORONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP OVERVIEW

Contrast Induced Nephropathy

In the name of GOD. Animal models of cardiovascular diseases: myocardial infarction & hypertension

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS

Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome

Coronary atherosclerotic heart disease remains the number

Inhibition of Vasoconstriction by Angiotensin Receptor Antagonist GR117289C in Arterial Grafts

Useful? Definition of High-risk? Pre-OP/Intra-OP/Post-OP? Complication vs Benefit? Mortality? Morbidity?

Control of blood tissue blood flow. Faisal I. Mohammed, MD,PhD

Journal of the American College of Cardiology Vol. 38, No. 7, by the American College of Cardiology ISSN /01/$22.

Journal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.

The Influence of Previous Percutaneous Coronary Intervention in Patients Undergoing Off-Pump Coronary Artery Bypass Grafting

For more information about how to cite these materials visit

DESCRIPTION: Percentage of patients aged 18 years and older undergoing isolated CABG surgery who received an IMA graft

University of Florida Department of Surgery. CardioThoracic Surgery VA Learning Objectives

BUFFERING OF HYDROGEN LOAD

Pathophysiology of Coronary Microvascular Dysfunction

Hypertension. Penny Mosley MRPharmS

Introduction. Invasive Hemodynamic Monitoring. Determinants of Cardiovascular Function. Cardiovascular System. Hemodynamic Monitoring

Vasospasm is an important concern in coronary artery

CONTEMPORARY USE OF ARTERIAL GRAFTS DURING CORONARY ARTERY BYPASS SURGERY: PARADIGM SHIFT? OR A LITTLE (MORE) TALK THAT NEEDS A LOT MORE ACTION

Heart Failure (HF) Treatment

Cardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.

Lab Period: Name: Physiology Chapter 14 Blood Flow and Blood Pressure, Plus Fun Review Study Guide

Controversies in Cardiac Surgery

Pharmacology. Drugs affecting the Cardiovascular system (Antianginal Drugs)

Magnesium is a key ionic modulator of blood vessel

Disclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin

Reoperative Coronary Artery Bypass Grafting: Analysis of Early And Late Outcomes

Case year old female nursing home resident with a hx CAD, PUD, recent hip fracture Transferred to ED with decreased mental status BP in ED 80/50

Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014

Novel insights into the complexity of ischaemic heart disease derived from combined coronary pressure and flow velocity measurements van de Hoef, T.P.

Rationale for Prophylactic Support During Percutaneous Coronary Intervention

Hawthorn Extract - Viable Treatment for Cardiovascular Disease or Unscrupulous Herbal Supplement?

Diabetes and Occult Coronary Artery Disease

Diabetes and Heart Failure

Acute Kidney Injury after Cardiac Surgery: Incidence, Risk Factors and Prevention

CURRENT STATUS OF STRESS TESTING JOHN HAMATY D.O.

Ischaemic heart disease. IInd Chair and Clinic of Cardiology

Lutonix in AV fistula and Early look AV IDE trial data

PHENTOLAMINE MESYLATE INJECTION SANDOZ STANDARD 5 mg/ ml THERAPEUTIC CLASSIFICATION Alpha-adrenoreceptor Blocker

Ischemic heart disease

ESC Congress 2011 SIMULTANEOUS HYBRID REVASCULARIZATION OF CAROTID AND CORONARY DISEASE INITIAL RESULTS OF A NEW THERAPEUTIC APPROACH

Effects of Intravenous Dobutamine on Coronary Vasomotion in Humans

Potassium-Induced Release of Endothelium- Derived Relaxing Factor From Canine Femoral Arteries

FEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery

Emergency surgery in acute coronary syndrome

BIPN100 F15 Human Physiol I (Kristan) Lecture 14 Cardiovascular control mechanisms p. 1

Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD

Effects of Selective 1 - and 2 -Adrenergic Blockade on Coronary Flow Reserve After Coronary Stenting

β adrenergic blockade, a renal perspective Prof S O McLigeyo

Hemodynamic improvement upon levosimendan treatment in low cardiac output patients following coronary artery bypass graft

Concentration of drug [A]

SUPPLEMENTAL MATERIAL

AUTONOMIC DRUGS: ADRENOCEPTOR AGONISTS AND SYMPATHOMIMETICS. Lecture 4

FFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium

Chapter 14 Blood Vessels, Blood Flow and Pressure Exam Study Questions

Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?

Prof. Samir Morcos Rafla Alexandria Univ. Cardiology Dept.

2017 Cardiology Survival Guide

Transcription:

doi: 10.5761/atcs.oa.14-00176 Original Article Vasodilation Responses to Non-Selective α-adrenergic Blockage of Coronary Bypass Grafts in Diabetic and Non-Diabetic Patients: In Vitro Study Selami Gurkan, MD, 1 Ozcan Gur, MD, 1 Demet Ozkaramanli Gur, MD, 2 Semil Selcen Gocmez, MD, 3 and Turan Ege, MD 4 Background: Adrenergic tonus is increased in atherosclerotic coronary arteries. In this study, we aimed to demonstrate in vitro effects of phentolamine, a reversible nonselective alpha (α) adrenergic blocker, on coronary artery bypass grafts (CABG) and compare its effects in diabetic and nondiabetic patients. Methods: A total number of 30 patients (15 diabetic and 15 nondiabetic) who were assigned to elective CABG surgery were enrolled into the study. For both groups of patients, 16 internal mammarian artery (IMA) samples, 16 saphenous vein (SV) samples and 16 radial artery (RA) samples were collected and studied in the tissue bath system. The vasodilatation responses to increasing doses of phentolamine were recorded. Results: When grafts were compared in terms of amount of vasodilatation to phentolamine, IMA had the most prominent vasodilatation followed by RA and SV respectively. Although the vasodilatation responses in nondiabetic patients were numerically higher than diabetic patients, there was no statistically difference between the groups. Conclusion: Phentolamine, a nonselective α adrenergic blocker, is proven to have equal vasodilatory effects in diabetic and nondiabetic CABG grafts and can safely be used both intravenously and topically in the perioperative period. Keywords: phentolamine, coronary artery bypass graft, vasodilatation Background Coronary atherosclerosis is usually accompanied by increased adrenergic tonus that predisposes coronary 1 Department of Cardiovascular Surgery, Namık Kemal University Hospital, Tekirdag, Turkey 2 Department of Cardiology, State Hospital, Tekirdag, Turkey 3 Department of Pharmacology, Namık Kemal University Hospital, Tekirdag, Turkey 4 Department of Cardiovascular Surgery, Trakya University Hospital, Edirne, Turkey Received: June 22, 2014; Accepted: August 11, 2014 Corresponding author: Selami Gurkan, MD. Namik Kemal Universitesi Hastanesi, Kalp Damar Cerrahisi Klinigi, 59100 Tekirdag, Turkey Email: gurkancem@yahoo.com 2014 The Editorial Committee of Annals of Thoracic and Cardiovascular Surgery. All rights reserved. vasoconstriction. 1,2) In the case of moderate to severe coronary stenosis, increased α adrenergic tonus induces myocardial ischemia. In the presence of ischemia and congestive heart failure; the number of β1 adrenergic receptors decrease and the α adrenoceptors increase and externalize further attenuating ischemia. 3) Blockage of the α-adrenergic system results in inhibition of vasoconstriction induced by endogenous catecholamines in vascular smooth muscle, and suppression of insulin secretion and lipolysis. 1) Although neglected in the contemporary medical practice, the use of α adrenergic blockers in reducing coronary resistance is well established. 4 6) Additionally, they were once used as vasodilatory agents in the presence of increased levels of catecholamines as in the case of heart failure or in low output states following open heart surgery. 7,8) 1

Gurkan S, et al. In this study, we sought to investigate in vitro effects of phentolamine, a reversible nonselective α adrenergic blocker, on coronary artery bypass grafts to elucidate the variability of adrenergic tonus among different graft types. Secondly, the grafts samples from diabetic and nondiabetic patients were compared to uncover the effect of diabetes mellitus on adrenergic tonus of bypass grafts. Materials and Methods Patient selection A total number of 30 patients (15 diabetic and 15 nondiabetic) who were planned to undergo elective coronary artery bypass grafting (CABG) surgery were prospectively enrolled into the study between January 2013 July 2013. Patients diagnosed with Type 2 diabetes mellitus were included as diabetic group. Before initiating the study, the ethics committee of our faculty approved the study and informed consent was obtained from all patients. The diabetic patients constituted the Group 1 and nondiabetic patients constituted Group 2. For both groups of patients, 16 pieces of internal mammarian artery (IMA), 16 radial artery (RA) and 16 saphenous vein (SV) graft samples were collected. The demographic and operative data of the patients are presented in Table 1. Graft preparation After excision of grafts for CABG, the surplus distal ends were used for the purpose of study. Both IMA and RA grafts were harvested together with the adjacent tissue with the aid of scissors and/or electrocautery. For the collection of the RA grafts, nondominant arm with adequate ulnar collateral circulation, assessed by Allen s test, was selected. Radial artery was not used in patients with the history of RA cannulation, subclavian stenosis, inadequate ulnar circulation or need for a future arteriovenous fistula. The SV grafts were excised without pedicle. No vasodilatory agent was used during preparation of the grafts. Tissue bath system The graft samples from IMA, RA and SV were transferred from operating room to the vascular laboratory in +4 C Krebs Solution (Composition: 122 mmol/l sodium chloride (NaCl), 5 mmol/l potassium chloride (KCl), 1.25 mmol/l calcium chloride (CaCl 2 ), 25 mmol/l sodium hydrogen carbonate (NaHCO 3 ), 1.2 mmol/l magnesium sulphate (MgSO 4 ), 1.0 mmol/l monopotassium phosphate (KH 2 PO 4 ), and 11.5 mmol/l glucose) in 5 min. The reservoirs in the tissue bath system were filled with 20 ml of 37 C Krebs solution which was continuously oxygenated with Carbogene gas of 95% O 2 and 5% CO 2 and changed every 20 minutes to keep the tissues alive. After removal of adjacent fatty tissues and adventitia, the grafts were sliced into 3 mm wide vascular rings and were suspended into the tissue bath system through steel hooks. The upper ends were attached to the transducer and the lower ends were kept stable. The vascular rings were entrained by 2 3 gr of active tension which was applied for 60 min and by KCl. Then the tissues were sub maximally contracted by 10 6 M phenylephrine (Sigma) in order to elucidate the any vasodilation response to phentolamine mesilate (Regitin Ampule; Novartis, Bern, Switzerland). Phentolamine was then added to the tissue bath system cumulatively starting from a concentration of 10 10 M in 2 min intervals and the dose was incremented half logarithmically until a concenration of 10 4 M was achieved. The data were transferred to the computer with the help of the Transducer Acquisition System (MAY IOBS 99, FDT 05; Commat, Ankara, Turkey) and stored with MAY- MASTER MP36 analysis software. Statistical Analysis The demographic variables were analyzed by SPSS 19 for Mac, and a p value <0.05 was considered to be statistically significant. Concentration-response curves were obtained by Graphpad Prism 6 Software Demo Version. Nonlinear regression analysis and One Way ANOVA was applied to the graphics. Results The demographic data of diabetic and non-diabetic patients were similar with no statistically significant difference (Table 1). After submaximal vasoconstriction of graft samples from diabetic (Group 1) and non-diabetic patients (Group 2) by phenilephrine, vasodilatation responses induced by incrementing doses of phentolamine were recorded. The data on percent vasodilatation and log EC50 (logarithmic half maximal effective concentration) values of different graft types are presented in Table 2. When the samples from IMA, RA and SV grafts were compared in terms of amount of vasodilatation response to phentolamine, IMA graft samples exhibited the most pronounced vasodilatation in both groups. The %vasodilatation responses with phentolamine were 95.12% ± 5.69% for IMA, 85.8% ± 7.33% for RA and 63.06% ± 4.72% 2

Table 1 Preoperative characteristics and operative data of patients Group 1 DM Group 2 NON-DM p values Age 63.53 ± 9.17 62.73 ± 9.21 >0.05 Euroscore 4.53 ± 1.24 2.53 ± 0.83 >0.05 HT 12 (80%) 12 (80%) >0.05 Preop EF 56.66 ± 6.1 53.13 ± 8.42 >0.05 COPD 2 (13.3%) 3 (20%) >0.05 No.of grafts 2.66 ± 0.89 2.53 ± 0.83 >0.05 CBT 66.46 ± 24.45 65.13 ± 24.58 >0.05 CCT 38.33 ± 14.22 37.66 ± 13.85 >0.05 ICU Stay 2.26 ± 0.59 2.13 ± 0.35 >0.05 Hospital Stay 5.93 ± 1.33 5.06 ± 0.25 >0.05 DM: diabetes melitus; HT: hypertension; EF: ejection fraction; COPD: chronic obstructive pulmonary disease; CBT: cardiopulmonary bypass time; CCT: cross clamp time; ICU: intensive care unit Responses of Coronary Bypass Grafts to Phentolamine Table 2 Vasodilatation responses to phentolamine Diabetic Nondiabetic p values %VD logec50 %VD logec50 IMA 95.12 ± 5.69 6.464 109.91 ± 11.65 6.063 0.717 RA 85.8 ± 7.33 6.261 91 ± 6.99 6.261 0.862 SV 63.06 ± 4.72 5.994 70.18 ± 6.03 2.816 8.890 %VD: percent vasodilatation; IMA: internal mammarian artery; RA: radial artery; SV: saphenous vein for SV. The log EC values in diabetic patients were 6.464 for IMA, 6.261 for RA and 5.994 for SV. For non-diabetic patients on the other hand, %vasodilatation responses with phentolamine were 109.91% ± 11.65% for IMA, 91.73% ± 6.99% for RA and 70.18% ± 6.03% for SV. The log EC values in non-diabetic patients were 6.063 for IMA, 6.261 for RA and 2.816 for SV. Although the %vasodilatation responses in non-diabetic patients were numerically higher than diabetic patients, there was no statistically difference between the two groups. Figures 1 3 demonstrates the concentration-response curves of IMA, RA and SV grafts in Groups 1 and 2 respectively. Discussion Alpha adrenergic system regulates the tonus of arterial and venous vasculature. 2,3) Activation of α-1 aderenoceptors causes an increase in intracellular Ca +2 in vascular smooth muscle and results in vasoconstriction and increase in blood pressure. Alpha-2 adrenoceptors, on the other hand are mainly presynaptic causing a biphasic blood pressure response when activated; a hypotensive response after a short period of hypertensive phase which is believed to be the result of its distinguished subtypes. 9) Fig. 1 Vasodilatation response curves of internal mammarian arteries. In this study, we have tried to demonstrate the effects of nonselective α adrenergic blockage (by phentolamine) on CABG grafts in diabetic and non-diabetic patients. Animal and human studies revealed that α 2 adrenergic receptors are mainly situated at microvascular circulation, while α 1 adrenergic receptors are more abundant at epicardial coronary arteries. 10,11) Endothelial dysfunction in atherosclerotic coronary arteries is shown to increase α adrenergic tonus through rising the number of receptors. Baumgart, et al. have documented that α agonists stimulate vasoconstriction in both conduit and resistant arteries 3

Gurkan S, et al. Fig. 2 Vasodilatation response curves of radial arteries. Fig. 3 Vasodilatation response curves of saphenous veins. in patients with coronary artery disease aggravating ischemia. 1) Moreover, both nonselective and selective α 1 blockage are shown to prevent vasoconstriction induced by cold pressors, exercise or cigarette smoking. 12) Studies to characterize the specific adrenoceptor types in IMA, SV and RA revealed that, RA and IMA grafts are well equipped with α 1 receptors and a relatively thicker layer of smooth muscle, while SV grafts possess both α 1 and α 2 adrenoceptors but little smooth muscle. 13) In our study, we showed that the vasodilatation response to phentolamine was most prominent in the IMA grafts, followed by RA and SV grafts. Diabetes Mellitus (DM) is associated with accelerated atherosclerosis mainly as a result of severe endothelial dysfunction. 14) In particular, in type 2 DM, vascular smooth muscle dysfunction and increased circulating levels of edothelin-1 contributes to coronary vasoconstriction. 15 17) Thus, α adrenergic tonus is expected to be more prominent in diabetic patients. Through this study, we aimed to compare the response to nonselective α blockage in diabetic and non-diabetic patients. Although the vasodilatation response to phentolamine was numerically higher in non-diabetic patients, we could not demonstrate any statistically significant difference between the two groups. Main explanation for this finding is the mechanism of vasodilatation caused by α antagonists which is via smooth muscle. Therefore, deranged endothelial function in diabetics may not necessarily influence the adrenergic tonus of the vessel. Another factor contributing to the diminished difference between diabetic and non-diabetic patients is the fact that the α adrenoceptors increase in number only in atherosclerotic vessels. Thus, IMA, RA and SV grafts are preserved with better vascular tone. 1) Phentolamine is currently used as a parenteral vasodilatory agent in hypertensive crisis of pheochromacitoma, cocaine associated myocardial ischemia, in high systemic vascular resistance states of severe congestive heart failure and hypertensive and/or low output states after cardiac surgery. 1) All these medical conditions represent high levels of circulating chatecholamines. Present study has showed that, phentolamine can safely be used postoperatively in the need for a vasodilator agent. Moreover, it can also be used locally to treat graft spasm in both arterial and venous grafts. In order to determine the efficacy of phentolamine at receptor level, both endothelialized and de-endothelialized tissue samples should have been used. This is one of the limitations of our study. The other limitation is the relatively small sample size. Conclusion In conclusion, phentolamine, a nonselective blocker, is proven to have equal vasodilatory effects in diabetic and nondiabetic CABG grafts and can safely be used both intravenously and topically in the perioperative period. Disclosure Statement None declared. References 1) Baumgart D, Haude M, Görge G, et al. Augmented alpha-adrenergic constriction of atherosclerotic human coronary arteries. Circulation 1999; 99: 2090-7. 2) Heusch G, Baumgart D, Camici P, et al. alpha-adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation 2000; 101: 689-94. 3) Heusch G. Alpha-adrenergic mechanisms in myocardial ischemia. Circulation 1990; 81: 1-13. 4

Responses of Coronary Bypass Grafts to Phentolamine 4) Kern MJ, Horowitz JD, Ganz P, et al. Attenuation of coronary vascular resistance by selective alpha 1-adrenergic blockade in patients with coronary artery disease. J Am Coll Cardiol 1985; 5: 840-6. 5) Gregorini L, Fajadet J, Robert G, et al. Coronary vasoconstriction after percutaneous transluminal coronary angioplasty is attenuated by antiadrenergic agents. Circulation 1994; 90: 895-907. 6) Gregorini L, Marco J, Kozàkovà M, et al. Alphaadrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction. Circulation 1999; 99: 482-90. 7) Lemmer JH, Botham MJ, McKenney P, et al. Norepinephrine plus phentolamine improves regional blood flow during experimental low cardiac output syndrome. Ann Thorac Surg 1984; 38: 108-16. 8) Kirsh MM, Bove E, Detmer M, et al. The use of levarterenol and phentolamine in patients with low cardiac output following open-heart surgery. Ann Thorac Surg 1980; 29: 26-31. 9) Ruffolo RR, Nichols AJ, Stadel JM, et al. Structure and function of alpha-adrenoceptors. Pharmacol Rev 1991; 43: 475-505. 10) Jones CJ, DeFily DV, Patterson JL, et al. Endotheliumdependent relaxation competes with alpha 1- and alpha 2-adrenergic constriction in the canine epicardial coronary microcirculation. Circulation 1993; 87: 1264-74. 11) Heusch G, Deussen A, Schipke J, et al. Alpha 1- and alpha 2-adrenoceptor-mediated vasoconstriction of large and small canine coronary arteries in vivo. J Cardiovasc Pharmacol 1984; 6: 961-8. 12) Barbato E, Bartunek J, Aarnoudse W, et al. Alphaadrenergic receptor blockade and hyperaemic response in patients with intermediate coronary stenoses. Eur Heart J 2004; 25: 2034-9. 13) He GW, Yang CQ. Characteristics of adrenoceptors in the human radial artery: clinical implications. J Thorac Cardiovasc Surg 1998; 115: 1136-41. 14) Raymond T, Raymond R, Lincoff AM. Management of the patient with diabetes and coronary artery disease: a contemporary review. Future Cardiol 2013; 9: 387-403. 15) DeFily DV, Nishikawa Y, Chilian WM. Endothelin antagonists block α1-adrioles. Am J Physiol Heart Circ Physiol 1999; 276: 1028-34. 16) Montero D, Walther G, Pérez-Martin A, et al. Vascular smooth muscle function in type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetologia 2013; 56: 2122-33. 17) Tiefenbacher CP, DeFily DV, Chilian WM. Requisite role of cardiac myocytes in coronary alpha1-adrenergic constriction. Circulation 1998; 98: 9-12. 5